Summary
It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case–control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32–4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% Cl 1.54–5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bokhman, JV (1983). Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10.
Booth, M, Beral, V & Smith, P (1989). Risk factors for ovarian cancer: a case–control study. Br J Cancer 60: 592–598.
Cramer, DW, Hutchinson, GB, Welch, WR, Scully, RE & Ryan, KJ (1983). Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71: 711–716.
Dennerstein, L, Shelly, J, Smith, AMA & Ryan, M (1994). Hysterectomy experience among mid-aged Australian women. Med J Aust 161: 311–313.
Faulkner, RL & Riemenschneider, EA (1945). Reactivation of endometriosis by stilbestrol therapy. Am J Obstet Gynecol 105: 560.
Garg, PP, Kerlikowske, K, Subak, L & Grady, D (1998). Hormone replacement therapy and risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92: 472–479.
Grady, D, Gebretsadik, T, Kerlikowske, K, Ernster, V & Petitti, D (1995). Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304–313.
Green, A, Purdie, D, Green, L, Dick, M-L, Bain, C & Siskind, V (1997a). Validity of self-reported hysterectomy and tubal sterilisation. Aust N Z J Public Health 21: 337–340.
Green, A, Purdie, D, Bain, C, Siskind, V, Russell, P, Quinn, M & Ward, B (1997b). Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Int J Cancer 71: 948–951.
Green, PK, Weiss, NS, McKnight, B, Voigt, LF & Beresford, SAA (1996). Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7: 575–580.
Greven, KM & Corn, BW (1997). Endometrial cancer. Curr Probl Cancer 21: 65–127.
Hartge, P, Hoover, R, McGowan, L, Lesher, L & Norris, HJ (1988). Menopause and ovarian cancer. Am J Epidemiol 127: 990–998.
Hempling, RE, Wong, C, Piver, MS, Natarajan, N & Mettlin, CJ (1997). Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89: 1012–1016.
International Agency for Research on Cancer (1987). Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs, Vol 1–42. IARC Monogr Eval Carcinog Risk Chem Hum (Suppl 7), pp 280–283. IARC: Lyon.
Kaufman, DW, Kelly, JP, Welch, WR, Rosenberg, L, Stolley, PD, Warshauer, ME, Lewis, J, Woodruff, J & Shapiro, S (1989). Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 130: 1142–1151.
La Vecchia, C, Liberati, A & Franceschi, S (1982). Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 69: 1207
Metzger, DA & Haney, AF (1989). Etiology of endometriosis. Obstet Gynecol Clin North Am 16: 1–14.
Paganini-Hill, A, Ross, RK & Henderson, BE (1989). Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 59: 445–447.
Paulson, RJ (1997). Fertility drugs and ovarian epithelial cancer: the endometriosis hypothesis. J Assist Reprod Genet 14: 228–230.
Purdie, D, Green, A, Bain, C, Siskind, V, Ward, B, Hacker, N, Quinn, M, Wright, G, Russell, P & Susil, B (1995). Reproductive and other factors and risk of epithelial overian cancer: an Australian case-control study. Int J Cancer 62: 678–684.
Risch, HA (1996). Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63: 254–257.
Rodriguez, C, Calle, EE, Coates, RJ, Miracle-McMahill, HL, Thun, MJ & Health, CW (1995). Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141: 828–835.
Russell, P (1994). Surface epithelial-stromal tumors of the ovary. In: Blaustein’s Pathology of the Female Genital Tract, 4th edn Kurman RJ Springer-Verlag: New York, 705–782.
Sainz de la Cuesta, R, Eichhorn, JH, Rice, LW, Fuller, AF Jr, Nikrui, N & Goff, BA (1996). Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60: 238–244.
Scully, RE (1977). Ovarian tumors. Am J Pathol 87: 686–720.
Smith, M & McCartney, AJ (1985). Occult, high-risk endometrial cancer. Gynecol Oncol 22: 154.
Weiss, NS, Lyon, JL, Krishnamurthy, S, Dietert, SE, Liff, JM & Daling, JR (1982). Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68: 95–98.
Whittemore, AS, Harris, R & Itnyre, J, The Collaborative Ovarian Cancer Group (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136: 1184–1203.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Purdie, D., Bain, C., Siskind, V. et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81, 559–563 (1999). https://doi.org/10.1038/sj.bjc.6690731
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690731
Keywords
This article is cited by
-
Ovarian epithelial tumors and reproductive factors: a systematic review
Archives of Gynecology and Obstetrics (2013)
-
Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum
Modern Pathology (2011)
-
Identification of common mechanisms between endometriosis and ovarian cancer
Journal of Assisted Reproduction and Genetics (2011)
-
Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition
Cancer Causes & Control (2011)
-
Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis
International Journal of Clinical Oncology (2009)